Zelda Therapeutics (ASX:ZLD) name change

Company News

by Ortenzia Borre

Zelda Therapeutics (ASX:ZLD) has confirmed the company has officially changed its name to Zelira Therapeutics following approval by shareholders and confirmation from ASIC.

The company’s ASX code will remain ZLD.

The global therapeutic medicinal cannabis company is currently undertaking human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA as well a pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Shares in Zelira Therapeutics (ASX:ZLD) closed flat at $0.07 yesterday.